5 Stocks With Exponential Upside Potential Before 2030

Most investors spend all their energy hunting for the next stock that can double. But the real fortunes, the ones that actually change a portfolio, come from the rare handful that go up 5 or 10 times over. 

So today, 5 companies worth walking through that still have a realistic shot at that kind of run between now and 2030, and as always, the best one is saved for last.

Daktronics (DAKT)

We will start with Daktronics (DAKT).

Most people draw a blank on the name, but there's a good chance you've stared at their product. They make the giant LED video screens, the stadium scoreboards, the highway billboards, the message boards at the airport. If it's a big, bright screen out in the real world, there's a good chance Daktronics built it.

This one came off a screen built for exactly this kind of hunt, the Potential Tenbaggers screen on WallStreetZen. Everywhere you look, the old fixed signage is getting torn out and replaced with big programmable LED, stadiums upgrading scoreboards, retailers and highways going digital, and that replacement cycle runs straight through Daktronics. Last quarter they came in way ahead of expectations, with earnings of 27 cents against a 20-cent forecast.

And it's not just a good business, it's a cheap one. Daktronics trades at a PEG ratio right around 1.1. PEG is the price-to-earnings ratio adjusted for growth, and under 1 is considered cheap, so at 1.1, you're getting that growth at a reasonable price.

Here's the unusual Wall Street angle. This company is covered by exactly one analyst. Just one. That analyst gives Daktronics a Strong Buy recommendation, with a price target well above where the stock trades today. When the rest of the Street initiates coverage, that catching-up can be its own tailwind.

And the quant model backs the story. Daktronics earns a Zen Rating of B, a Buy recommendation, in the top 7% of the more than 4,600 stocks the system tracks. That rating comes out of 115 different factors, here are the ones that matter.

Financials come in at the top 21%. Value, the top 16%. Sentiment, the top 16%. And the standout, Safety, at the top 11%, and Safety isn't about debt, it's about how steady and predictable the earnings and share price have been.

To keep it honest, this is lumpy, project-based revenue, so a big contract can make one quarter look huge and the next one quiet.

But a business at the center of that shift to programmable LED, priced reasonably, with coverage this thin, that's a beautiful setup to keep watching. Daktronics is the quiet one on this list. The next name is anything but.

Corcept Therapeutics (CORT)

Next up, Corcept Therapeutics (CORT).

For years, Corcept was a one-drug company. That drug treats a serious hormonal disorder, the body making far too much of the stress hormone cortisol. A good, profitable business. But here's why the timing is exciting now, that's finally changing.

Earlier this year the FDA approved their second major drug, a cortisol therapy for a hard-to-treat ovarian cancer, and the early launch is running strong. That pushed last quarter's earnings to sail right past the forecast, 36 cents against a 2-cent estimate, and management raised guidance again.

Now, the chart is up sharply already, shares are up more than 100% over the past 3 months. But the move doesn't look over.

Looking ahead, earnings are forecast to grow at a rate of almost 130% per year, against an industry average of just 12%. And the second drug is only the start, there's another application back in front of the FDA, and more cortisol-based candidates behind it in testing. That's what can keep a trajectory going, even after a run like this.

Wall Street is bullish. Most of the analysts covering Corcept land on a Strong Buy recommendation. And there's a nice cluster, 3 analysts who are at the very top of everyone tracked in terms of actual stock picking performance, with price targets that imply upside of more than 40%.

The model likes it even more. Corcept earns a Zen Rating of A, a Strong Buy recommendation, and it lands in the top 1% of every stock tracked. Here's what's underneath.

Value comes in at the top 19%, rare for a biotech this far into a breakout. Sentiment, the top 16%. Financials, the top 17%, and unlike most biotechs at this stage, this one actually makes money. Momentum, the top 4%. And the standout, Growth, also at the top 4% of the entire market.

The honest risk: a recent court decision cracked open the door for a generic version of that original hormone disorder drug, so that revenue stream faces pressure down the line. That's the whole reason the second drug and the pipeline matter so much, if the cancer franchise delivers, this company could look dramatically bigger by 2030. But on the whole, this is a good valuation, strong growth, real profits, and the smart money moving in all at once.

From a biotech breaking out, on to a name you'd never guess is a growth story.

Generac (GNRC)

Let's forge ahead to Generac (GNRC).

Generac is a backup generator company, when the power goes out, and your neighbor's house is the only one on the block with the lights still on, odds are that's a Generac humming away in the yard. But that's just one part of the story. They've built out a whole clean-energy ecosystem around that core, home battery storage, solar components, smart energy management, right as the grid gets more strained and more people want backup power they can control themselves. And here's the part the market's most excited about: they've moved into backup power for data centers, supplying the big megawatt systems that keep AI facilities running when the grid can't.

Last quarter they beat expectations cleanly, earnings of $2.91 against a $2.01 forecast. The quarter before was also a blowout.

And it's not looking like a two-quarter story, earnings are forecast to grow better than 45% a year going forward, twice as fast as its industry average.

Now, this stock has actually pulled back, down better than 20% over the past 3 months. And the reason is telling. Last quarter Generac slightly missed on revenue and trimmed its outlook for home generators, and the market sold it off. But take a closer look at the full earnings report: total sales still grew better than 10%, earnings crushed the forecast, and the real engine now is data-center and commercial power, where the backlog runs into 2027 and beyond. The market punished a soft residential number and looked right past the part that's actually driving the growth.

Wall Street hasn't been swayed by the pullback. GNRC has wide coverage, 15 analysts, with 11 giving it a Strong Buy recommendation. The most bullish price target implies an upside of more than 55% from where the stock is now.

The model agrees. Generac earns a Zen Rating of A, a Strong Buy recommendation, in the top 2% of all the stocks tracked. Here's the component walk.

Value comes in around the top 26%, so even after the run it's reasonably priced. Safety, the top 16%. Sentiment, the top 13%. Financials, the top 10%, a genuinely strong balance sheet. And the standout, Growth, at the top 2% of the entire market.

The one thing to watch: a lot of the growth story now leans on a handful of big data-center customers, so any slowdown in that spending would be felt.

But look at the big picture. A company growing fast, on solid financials, with the smart money already positioned, on sale after a pullback, that's worth watching into 2030.

The next name proves the most boring-sounding business on a list can hide the most interesting setup.

DHI Group (DHX)

Stock number four is DHI Group (DHX).

This one has the most boring-sounding business on the list and one of the more interesting setups. DHI runs specialized job boards. Two platforms, Dice, for technology professionals, and ClearanceJobs, and ClearanceJobs is the part that matters. It's the go-to hiring marketplace for people who hold U.S. government security clearances. Defense, intelligence, classified work. You can't fill those roles off a general job site, and that is the moat.

With defense and government spending climbing, demand for cleared talent climbs right along with it. And DHI has been pushing ClearanceJobs deeper into that defense hiring world, turning a job board into a piece of the pipeline itself. In the last 2 quarters, earnings per share came in significantly ahead of estimates.

The Wall Street coverage on this one is interesting. It's a $165 million market cap company, so it's little wonder there's not a ton of coverage, just 3 analysts. Here's the thing though: 2 of them have Strong Buy recommendations, the third has a Buy recommendation. Every one of their targets sits significantly above where the stock trades today, and the most bullish analyst, who ranks in the top 2% of everyone tracked, is calling for more than 160% upside. Yep, that's not a typo or error, 160%.

Now for what the system has to say. DHI earns a Zen Rating of A, a Strong Buy recommendation, and the overall fundamentals put it in the top 1% of everything tracked. Here are the grades.

Value comes in at the top 21%. Growth, the top 16%. Momentum, the top 18%. Financials, the top 11%. And the standout, Sentiment, at the top 9% of the market, the smart money is paying attention.

The honest risk: this is a small company, and much of the story rides on defense hiring staying strong, so if that spending cools, there's not a big cushion underneath it.

But a high-margin, cash-generating business plugged straight into defense spending, with analyst coverage this thin but this bullish, for a name this size, that's a lot to like. And it sets up the final stock perfectly, the purest example on this list of a tiny company on the cusp of something big.

Before we get to the last stock, one quick thing. If you want to stay one step ahead of the market, join the Live training every Monday. That is when we share the updated market outlook and trading plan to outperform, plus the Trade of the Week based on our proven Zen Ratings quant model.

It's a free event, but you do need to register. Just go to wallstreetzen.com/live. And if you can't make it live, register anyway, we'll send you the replay.

Precigen (PGEN)

As always, the best is saved for last. Here's something you almost never see. A company that spent years as a cash-burning science project with no approved product, and then one approval flipped the entire story overnight.

That's Precigen (PGEN). Precigen is a gene therapy company. And last August, everything changed, the FDA approved their lead therapy for a rare, painful airway disease. It's the first and only approved treatment for that condition, and the FDA handed them seven years of market exclusivity, no competitor can bring a copycat in that window. A protected runway for a first-of-its-kind medicine.

And the launch is ramping fast. Revenue is forecast to grow at around 70% a year going forward, more than double the pace of the broader biotech industry.

You can watch it happen on the bottom line. Look at the earnings trend, the losses shrink quarter after quarter, and then last quarter they flip, 5 cents in earnings against a forecast of negative 1 cent. After years of burning cash, this company actually crossed into profit. A company turning the corner in real time is what it looks like to catch one of these early, before the whole market figures it out.

Now, this stock is not a secret, it's up nearly 300% over the past year. But the story isn't close to over. That approved drug is really just the opening act, there's an application under review to sell it across Europe, it's moving into treating children, and the same underlying platform that produced it has a second drug already in mid-stage cancer trials, with fresh data due by the end of this year. In other words, the thing that made this company profitable is only the first product off the line.

On Wall Street, coverage is still thin, which is what you'd expect this early, but both analysts on it have a Buy recommendation. The most up-to-date coverage comes from a top-2% ranked analyst, and his price target implies upside of 160%.

And this is where the model really lights up. Precigen earns a Zen Rating of A, a Strong Buy recommendation, in the top 1% of every stock tracked. Here are the components.

Financials come in at the top 24%. Momentum, the top 11%. The AI grade, the top 8%, and that factor measures how likely a stock is to outperform based on patterns in the data. Sentiment, the top 6%. And the standout, Growth, at the top 1% of every stock in the system.

Now to be straight about the risk: Safety grades near the bottom of the scale, in the bottom 5%. This is a small biotech leaning heavily on one drug, and it can be volatile.

But a first-and-only approved medicine, exploding revenue, a seven-year moat, a promising pipeline, and a top 1% rating, that's exactly the kind of setup that, if it plays out, produces the biggest winners on a list like this.

Conclusion

So there's the list of 5 stocks with exponential upside potential heading into 2030. Daktronics, the digital display leader Wall Street has barely looked at. Corcept, the biotech breaking out beyond a single drug. Generac, the home-energy brand on sale after a pullback. DHI Group, the defense-hiring small-cap the Street is only starting to notice. And Precigen, the gene therapy name with a first-and-only approved drug.

These grades update daily, so visit the quote pages on wallstreetzen.com to see the latest ratings for this or any other stock. You can pull a free rating on over 4,600 stocks yourself just by typing in a ticker.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.